Pharma Focus Asia

CohBar and Morphogenesis Enter into Merger Agreement

Wednesday, May 24, 2023

CohBar Morphogenesis announced that they have entered into a definitive agreement for an all-stock transaction forming a company combining expertise and resources to advance a late-stage oncology pipeline.

The combined company will focus on advancing Morphogenesis’ two technologies that seek to overcome the major obstacles that limit the effectiveness of current immunotherapies in treating cancer. Combined company will operate under the name “TuHURA Biosciences” and advance a personalised cancer vaccine platform and preclinical tumour microenvironment modulators.

The proposed merger with CohBar, which comes at a pivotal time for Morphogenesis aims to initiate Phase 2/3 registration study for IFx-Hu2.0 early next year. The technology platforms have the potential to significantly increase the number of cancer patients that respond to immunotherapies, such as checkpoint inhibitors. This transaction serves as a significant next step in the advancement of important mission.

Combining with Morphogenesis and leveraging their late-stage pipeline of novel immuno-oncology technologies represents the best path forward for stockholders and has the potential to deliver near and long-term value.

magazine-slider-imageMFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopNitrosamine Advance Workshop 2024CPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024Rehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024LogiPharma Asia 2024